Precision medicine allows patients to be divided into genetically defined sub-populations. This approach allows physicians to identify and treat patients with a therapeutic that is specific to their disease causing genetic variant.
Precision Medicine in AMD and Linked Diseases
Gemini Therapeutics is leveraging the proven principles of precision medicine to advance the evaluation and treatment of complex retinal diseases affecting millions of people.
Insights from our work on genetic risk factors and understanding of those risks at the molecular level has led us to modulation of the innate immune system and the complement pathway and its role in AMD.
While other efforts have largely focused on blocking the complement system, Gemini Therapeutics is developing a new class of therapeutics to restore regulation of the complement system.